Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
J Prosthet Dent ; 121(3): 381-383, 2019 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-30396710

RESUMEN

Many implant overdenture attachments accommodate divergent abutments. However, there can be instances where the denture base resin surrounding the abutment may impede seating by binding on the axial surface(s) of the abutment. This article describes the use of a dental surveyor to aid clinicians in determining where the resin denture base might be preventing the seating of overdenture attachments. The surveyor can be used for judicious adjustment to allow optimal seating of the attachments.


Asunto(s)
Implantes Dentales , Prótesis de Recubrimiento , Pilares Dentales , Prótesis Dental de Soporte Implantado , Bases para Dentadura , Retención de Dentadura
3.
Nat Med ; 26(2): 228-235, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-32015557

RESUMEN

Zika virus (ZIKV) has caused significant disease, with widespread cases of neurological pathology and congenital neurologic defects. Rapid vaccine development has led to a number of candidates capable of eliciting potent ZIKV-neutralizing antibodies (reviewed in refs. 1-3). Despite advances in vaccine development, it remains unclear how ZIKV vaccination affects immune responses in humans with prior flavivirus immunity. Here we show that a single-dose immunization of ZIKV purified inactivated vaccine (ZPIV)4-7 in a dengue virus (DENV)-experienced human elicited potent cross-neutralizing antibodies to both ZIKV and DENV. Using a unique ZIKV virion-based sorting strategy, we isolated and characterized multiple antibodies, including one termed MZ4, which targets a novel site of vulnerability centered on the Envelope (E) domain I/III linker region and protects mice from viremia and viral dissemination following ZIKV or DENV-2 challenge. These data demonstrate that Zika vaccination in a DENV-experienced individual can boost pre-existing flavivirus immunity and elicit protective responses against both ZIKV and DENV. ZPIV vaccination in Puerto Rican individuals with prior flavivirus experience yielded similar cross-neutralizing potency after a single vaccination, highlighting the potential benefit of ZIKV vaccination in flavivirus-endemic areas.


Asunto(s)
Dengue/inmunología , Donantes de Tejidos , Vacunas Virales/uso terapéutico , Infección por el Virus Zika/inmunología , Infección por el Virus Zika/prevención & control , Animales , Anticuerpos Monoclonales/inmunología , Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , Chlorocebus aethiops , Reacciones Cruzadas , Virus del Dengue , Mapeo Epitopo , Femenino , Flavivirus/metabolismo , Humanos , Inmunoglobulina G/química , Concentración 50 Inhibidora , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Unión Proteica , Dominios Proteicos , Vacunación , Vacunas de Productos Inactivados/uso terapéutico , Células Vero , Viremia , Virus Zika
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA